158 results
8-K
EX-99.1
MDGL
Madrigal Pharmaceuticals, Inc.
7 Aug 24
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
7:06am
in NASH/MASH and provide practical guidance for the appropriate use of Rezdiffra, including patient identification, assessment of response and general
8-K
EX-1.1
MDGL
Madrigal Pharmaceuticals, Inc.
7 May 24
Entry into a Material Definitive Agreement
4:36pm
extensions thereof, and have paid all material taxes required to be paid by any of them and, if due and payable, any related or similar assessment, fine
424B3
MDGL
Madrigal Pharmaceuticals, Inc.
7 May 24
Prospectus supplement
4:34pm
, Washington, D.C.
EXPERTS
The financial statements and management’s assessment of the effectiveness of internal control over financial reporting … will be passed upon by Hogan Lovells US LLP, Washington, DC.
EXPERTS
The financial statements and management’s assessment of the effectiveness
424B5
MDGL
Madrigal Pharmaceuticals, Inc.
7 May 24
Prospectus supplement for primary offering
4:29pm
York.
EXPERTS
The financial statements and management’s assessment of the effectiveness of internal control over financial reporting (which … upon by Hogan Lovells US LLP, Washington, DC.
EXPERTS
The financial statements and management’s assessment of the effectiveness of internal control
S-3ASR
MDGL
Madrigal Pharmaceuticals, Inc.
7 May 24
Automatic shelf registration
4:06pm
, Washington, DC.
EXPERTS
The financial statements and management’s assessment of the effectiveness of internal control over financial reporting (which
S-3ASR
EX-4.6
9su j1yicm
7 May 24
Automatic shelf registration
4:06pm
8-K
EX-1.1
2lwxoim3pysun287
20 Mar 24
Entry into a Material Definitive Agreement
4:11pm
424B5
cf3ke7
20 Mar 24
Prospectus supplement for primary offering
4:06pm
424B5
y3bix70ow9 u99y8980u
18 Mar 24
Prospectus supplement for primary offering
4:08pm
8-K
EX-99.1
972p2ykr4
14 Mar 24
Regulation FD Disclosure
6:47pm
8-K
EX-99.2
7um3fr7 h7h164a
14 Mar 24
Regulation FD Disclosure
6:47pm
8-K
EX-99.1
91f1bj
6 Nov 23
Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023
8:31am
8-K
EX-1.1
nk4hbs pcpmddsshb0t
2 Oct 23
Entry into a Material Definitive Agreement
5:15pm
424B5
1ykkjs
2 Oct 23
Prospectus supplement for primary offering
5:10pm
424B5
0o10vf7poc0f680ljub
28 Sep 23
Prospectus supplement for primary offering
4:01pm
S-8
EX-99.3
agu4rnzmg8dhi
11 Sep 23
Registration of securities for employees
4:31pm
424B3
e0p7r16
8 Aug 23
Prospectus supplement
9:19am